ArvinasARVN
Market Cap: $1.68B
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 445
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
546% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $1.02M
68% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 53
3.41% more ownership
Funds ownership: 100.15% [Q1] → 103.56% (+3.41%) [Q2]
6% less funds holding
Funds holding: 218 [Q1] → 204 (-14) [Q2]
33% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 43
33% less capital invested
Capital invested by funds: $2.81B [Q1] → $1.89B (-$926M) [Q2]
36% less funds holding in top 10
Funds holding in top 10: 11 [Q1] → 7 (-4) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 165 met price target | 257%upside $87 | Buy Reiterated | 1 Aug 2024 |
Wedbush Robert Driscoll 63% 1-year accuracy 31 / 49 met price target | 134%upside $57 | Outperform Reiterated | 31 Jul 2024 |
Barclays Peter Lawson 29% 1-year accuracy 8 / 28 met price target | 97%upside $48 | Overweight Maintained | 31 Jul 2024 |
Oppenheimer Matthew Biegler 38% 1-year accuracy 8 / 21 met price target | 105%upside $50 | Outperform Maintained | 31 Jul 2024 |